BTF Best of ASH & SABCS 2024, Phoenix

Scottsdale, AZ US
January 12, 2024 to January 13, 2024

The BTF Best of ASH & SABCS 2024, Phoenix, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. 

 

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee

Conference Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Co-Chairs:

Lida Mina, MD - Mayo Clinic, Phoenix

Tibor Kovacsovics, MD - City of Hope Phoenix

Organizing Committee

Qing Zhao, MD - MD Anderson Cancer Center

VENUE INFORMATION 

A limited number of rooms have been booked at the Hilton Scottsdale Resorts and Villas at a discounted nightly rate of $269 per room for this conference's attendees and sponsors. Please book your room at the link below by Monday, December 11, 2023, to receive the discounted group rate. 

Learning Objectives

  • Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  • Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  • Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  • Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  • Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.75 Contact Hours.
Course opens: 
09/20/2023
Course expires: 
03/30/2024
Event starts: 
01/12/2024 - 8:00am PST
Event ends: 
01/13/2024 - 6:00pm PST
Cost:
$150.00

All times are listed in Mountain Standard Time (MST).

DAY 1 - JANUARY 12TH, 2024

04:00 PM – 04:45 PM: Registration/Networking & Exhibits


04:45 PM – 05:00 PM: Opening Remarks by Conference Chairs


05:00 PM – 06:30 PM: Session 1 – Case-Based Discussion

Moderator: Tibor Kovacsovics, MD

Case 1 – Bleeding Disorder - Danielle Nance, MD

Case 2 – Clotting Disorder - Leslie Padrnos, MD

Case 3 – ITP/TTP - Margarita Kushnir, MD

Case 4 – Anemia - Soyoung (Sara) Park, MD

Case 5 – Bone Marrow Failure - Srinivas Tantravahi, MBBS, MRCP


06:30 PM – 07:15 PM: Networking/Reception & Exhibits


DAY 2 – JANUARY 13TH, 2024

07:00 AM – 07:55 AM: Breakfast & Exhibits

08:00 AM - 08:15 AM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD


08:15 AM – 09:45 AM: Session 2 

Moderator: Tibor Kovacsovics, MD

08:15 AM – 08:40 AM: MDS/Acute Leukemia - Tibor Kovacsovics, MD

08:40 AM – 09:05 AM: Myeloproliferative Neoplasms and CML - Idoroenyi Amanam, MD

09:05 AM – 09:30 AM: Cellular Therapy in Hematologic Malignancies – Recent Updates - Jeffrey Schriber, MD

09:30 AM – 09:45 AM: Q & A


09:45 AM – 10:00 AM: Break & Exhibits


10:00 AM – 11:45 AM: Session 3

Moderator: Sumit Madan, MD 

10:00 AM – 10:25 AM: Lymphoma - Leslie Popplewell, MD

10:25 AM – 10:50 AM: Chronic Lymphocytic Leukemia - Talal Hilal, MD

10:50 AM – 11:15 AM: Multiple Myeloma - Jeremy Larsen, MD

11:15 AM – 11:45 AM: Q & A


11:45 AM – 12:45 PM: Lunch & Exhibits

Product Theater Sponsored by AstraZeneca *Non CME Activity* in Sonora D Room

Topic: TRUQAP + fulvestrant: A Novel 2L Treatment Option for HR+/HER2- aBC or mBC With PIK3CA/AKT1/PTEN Alterations

Speaker: Nazish Ahmed, DO from Palo Verde Cancer Specialists


12:45 PM – 03:00 PM: Session 4

Moderators: Lida Mina, MD and Farah Raheem, PharmD

12:45 PM – 01:10 PM: Hormone Receptor Positive Breast Cancer - Shakeela Bahadur, MD

01:10 PM – 01:35 PM: HER2 Positive Breast Cancer - Brenda Ernst, MD

01:35 PM – 02:00 PM: Triple Negative and HER2 Low Breast Cancer - Karen Anderson, MD, PhD

02:00 PM - 02:25 PM: Molecular Targets in Breast Cancer and Genomics - Felipe Batalini, MD

02:25 PM – 03:00 PM: Q & A


03:00 PM - 03:15 PM: Break & Exhibits


03:15 PM - 04:30 PM: Session 5

Moderator: Julie Billar, MD

03:15 PM - 03:40 PM: Radiotherapy – Best Breast Practice - Carlos Vargas, MD

03:40 PM - 04:05 PM: Updates in Surgical Approach – Best Breast Practice - Patricia Cronin, MD, FRCS

04:05 PM - 04:30 PM: Q & A


04:30 PM - 05:00 PM: Case-Based Discussion

Moderator: Mei Wei, MD

Case 1 – Metaplastic Breast Cancer - Mark Pegram, MD

Case 2 – Inflammatory Breast Cancer - Karen Anderson, MD, PhD

Case 3 – High-Risk DCIS - Qing Zhao, MD

Panel Discussion: Shakeela Bahadur, MD


05:00 PM – 05:05 PM: Adjourn

Hilton Scottsdale Resort & Villa
6333 N Scottsdale Rd
Scottsdale, AZ 85250
United States

A limited number of rooms have been booked at the Hilton Scottsdale Resorts and Villas at a discounted nightly rate of $269 per room for this conference's attendees and sponsors. Please book your room at the link below by Monday, December 11, 2023, to receive the discounted group rate. 

Individuals must provide notice of cancellation at least 48 hours prior to scheduled arrival. Rates are subject to prevailing city and state tax, currently 14.02%
Additional person is $10.00 per night for more than double occupancy. Occupancy is limited to four (4) persons per guestroom

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Tibor Kovacsovics, MD

has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Syndax;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Glycomimetics;.
has a financial relationship (Other) with Servier;.

Lida Mina

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Tibor Kovacsovics, MD

has a financial relationship (Other) with Servier;.
has a financial relationship (Grant Or Contract) with Glycomimetics;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with Syndax;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Novartis;.

Sumit Madan

has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Karyopharm;.
has a financial relationship (Independent contractor) with Abbvie;.
Speaker/Topic Presenter(s)

Karen Anderson, Professor, Arizona State University, Mayo Clinic Arizona

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Stock Options) with FlexBioTech;.
has a financial relationship (Independent contractor) with Effector;.

Shakeela Bahadur

has a financial relationship (Professional Services) with Eli Lilly ;.

Felipe Batalini, M.D.

has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with CARIS;.
has a financial relationship (Financial Support) with Astrazeneca;.
has a financial relationship (Financial Support) with Illumina/Grail;.
has a financial relationship (Financial Support) with Novartis;.
has a financial relationship (Financial Support) with Daiichi-Sankyo;.
has a financial relationship (Financial Support) with Foundation Medicine;.

Patricia Cronin, MD FRCS FACS

has no relevant financial relationships to disclose at this time.

Brenda Ernst, MD

has no relevant financial relationships to disclose at this time.

Talal Hilal

has a financial relationship (Other) with BeiGene;.

Tibor Kovacsovics, MD

has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Glycomimetics;.
has a financial relationship (Other) with Servier;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Syndax;.

jeremy larsen

has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with Abbvie;.

Sara Park

has no relevant financial relationships to disclose at this time.

Leslie Popplewell

has a financial relationship (Professional Services) with novartis;.
has a financial relationship (Professional Services) with kite;.
has a financial relationship (Professional Services) with adc therapeutics;.

Jeff Schriber

has no relevant financial relationships to disclose at this time.

Carlos Vargas, MD

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Karen Anderson, Professor, Arizona State University, Mayo Clinic Arizona

has a financial relationship (Independent contractor) with Effector;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Stock Options) with FlexBioTech;.

Margarita Kushnir, MD

has no relevant financial relationships to disclose at this time.

Danielle Nance, MD

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with CSL Behring;.

Leslie Padrnos

has no relevant financial relationships to disclose at this time.

Mark Pegram, MD

has a financial relationship (Employment) with Rain Oncology;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Novartis;.

Srinivas Tantravahi, MBBS; MRCP

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Financial Support) with karyopharm therapeutics;.
has a financial relationship (Professional Services) with MorphoSys;.
has a financial relationship (Professional Services) with CTI BioPharma;.
has a financial relationship (Professional Services) with AbbVie;.
Moderator(s)

Julie Billar, MD

has no relevant financial relationships to disclose at this time.

Farah Raheem, PharmD, BCOP

has no relevant financial relationships to disclose at this time.

Mei Wei, MD

has a financial relationship (Other) with Gilead Science;.
Planning committee(s)

Qing Zhao

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.75 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.